Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.58 |
| ▸ | GSK3B | P49841 | 11/20 | 0.58 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13885152 | 0.85 | CDK2 (0.67) | CDK2GSK3BMAPKAPK2CHEK1CCNE1 | |
| SCHEMBL13885674 | 0.85 | CDK2 (0.66) | CDK2GSK3BMAPKAPK2CSNK2BCHEK1 | |
| SCHEMBL14528910 | 0.84 | CDK2 (0.47) | CDK2GSK3BMAPKAPK2CSNK2B | |
| SCHEMBL13998536 | 0.81 | GSK3B (0.54) | CDK2GSK3BMAPKAPK2CSNK2B | |
| SCHEMBL13998623 | 0.80 | GSK3B (0.55) | CDK2GSK3BMAPKAPK2CSNK2B | |
| SCHEMBL14427517 | 0.76 | CDK2 (0.70) | CDK2GSK3BMAPKAPK2CHEK1CCNE1 | |
| SCHEMBL14427515 | 0.75 | CDK2 (0.82) | CDK2GSK3BMAPKAPK2CHEK1CCNE1 | |
| SCHEMBL14427533 | 0.75 | CDK2 (0.65) | CDK2GSK3BMAPKAPK2CCNE1FLT3 | |
| SCHEMBL14427535 | 0.75 | CDK2 (0.78) | CDK2GSK3BMAPKAPK2CHEK1CCNE1 | |
| SCHEMBL14528908 | 0.74 | GSK3B (0.59) | CDK2GSK3BCHEK1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934224-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |